Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (January 2018)
17 slides from Alembic Pharmaceuticals's investor presentation, January 2018
Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation January-2018
Slide 2: Contents
Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Rhizen JV for NCE research Launched first NDA wit
Slide 5: Highlights – Q3FY18
Highlights – Q3FY18 Financial Highlights India Formulations Gr% Rs 3.07bn Rs 3.49bn 14% Particular (Rs bn) Q3FY17 Q3FY18 Gr% Net Sales 7.77 8.40 8% Specialty 10% EBITDA Pre R&D 2.62 2.81 7% 55% 54% Margin % 34% 33% R&D 1.21 0.98 -19% Acute 16% R&D % 16% 12% 36% 36% EBITDA Post R&D 1.45 1.88 29% Marg
Slide 6: Highlights – 9MFY18
Highlights – 9MFY18 Financial Highlights India Formulations Gr% Rs 9.70bn Rs 9.70bn Particular (Rs bn) 9MFY17 9MFY18 Gr% Net Sales 23.93 22.77 -5% Specialty -1% EBITDA Pre R&D 7.89 7.51 -5% 58% 57% Margin % 33% 33% R&D 3.15 2.90 -8% Acute 1% R&D % 13% 13% EBITDA Post R&D 4.80 4.68 -3% 33% 33% Margin
Slide 7: Highlights – FY17
Highlights – FY17 Financial Highlights India Formulations Gr% Rs 11.76bn Rs 12.55bn 7% Particular (Rs bn) FY16 FY17 Gr% Net Sales 31.62 31.31 -1% Specialty 13% EBITDA Pre R&D 13.13 10.25 -22% 54% 58% Margin % 42% 33% R&D 3.16 4.27 35% Acute -4% R&D % 10% 14% EBITDA Post R&D 10.07 6.11 -39% 37% 33% M
Slide 8: Business
Business Key Numbers (Rs bn) 4.8 HQ, Vadodara 3.2 1.3 Capex 31.6 31.3 20.7 Branded, Mumbai Generics, 10.1 Vadodara 6.1 4.3 India 4.1 3.2 1.3 International Generics Ex-India FY15 FY16 FY17 API Sales EBITDA R&D R&D: Manufacturing: Formulation: Vadodara and Hyderabad Formulation: Oral Solids, Panelav (
Slide 9: International Generics
International Generics Sales (Rs bn) ANDA Filed Filings: 119 CAGR 42% Approval: 70* 14.6 * Incl 9 tentative 12.4 20 13 5.6 5.9 8 7 3.0 4 FY13 FY14 FY15 FY16 FY17 FY13 FY14 FY15 FY16 FY17 R&D Spend (Rs bn) 13.6 Milestones and Update 10.0 6.6 6.3 5.1 Acquired US based Orit Laboratories LLC 4.3 7 Appro
Slide 10: India Formulations
India Formulations Sales (Rs bn) Marketing Organisation CAGR 9% 12.5 11.8 5000 + marketing team 11.0 9.7 8.7 17 marketing divisions 170 products, 15% of products in NLEM FY13 FY14 FY15 FY16 FY17 Therapy Split CAGR% Key Achievements % of Domestic Formulations 43 40 38 6% Successful key new launches 5
Slide 11: Therapy-wise Performance Q3FY18
Therapy-wise Performance Q3FY18 Q3 FY 2018 Q3 FY 2017 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 7 2.00 4 10 8 2.06 18 11 Anti Diabetic 10 1.65 7 4 15 1.70 19
Slide 12: Therapy-wise Performance 9MFY18
Therapy-wise Performance 9MFY18 9M FY 2018 9M FY 2017 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 5 2.03 4 5 9 2.05 19 15 Anti Diabetic 12 1.67 5 4 16 1.79 34
Slide 13: Therapy-wise Performance MAT DEC 17
Therapy-wise Performance MAT DEC 17 MAT DEC 2017 MAT DEC 2016 Therapy Market Alembic Therapy Market Alembic Therapy Growth Share Growth Growth Share Growth (ORG) (ORG) (ORG) (ORG) (ORG) (ORG) Cardiology 6 2.04 6 10 2.03 20 Anti Diabetic 13 1.68 8 17 1.76 34 Gynaecology 5 2.80 1 9 2.90 26 Gastrology
Slide 14: Strategy
Strategy R&D Pipeline Growth drivers Dosage Form FY14 FY18 R&D: Rapidly expand breadth and quality of pipeline Oral Solids Doubled internal OSD grid. injectable, dermatology ophthalmology and oncology. Expanded grid 5 fold Injectables Partnerships to gain time Build manufacturing capacities rapidly,
Slide 15: Financials – 5 years
Financials – 5 years Sales CAGR% Sales (Rs bn) CAGR 20% Rs 15.3bn Rs 31.3bn 20% 20% 31.6 31.3 23% API 16% 40% 20.7 18.7 57% India 9% 15.3 40% 20% International 42% FY13 FY14 FY15 FY16 FY17 FY13 FY17 EBITDA (Rs bn) 32% Net Profit (Rs bn) 23% 17% 19% 19% 20% 14% 13% 11% 13% 7.2 10.1 Margins% Margins%
Slide 16: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 13 Promoter & Promoter group 14 FI/FII/MF Public 73 Market capitalisation (Rs bn) CAGR 38% Total paid-up share capital 377.03mn 113 118 100 Total number of shares O/S 188.52mn 86 No. of shareholders >50 K 54 20 FY13 FY14 FY15 FY16 FY17 9MFY18
Slide 17: Thank You
THANK YOU
Alembic Pharmaceuticals — Investor Presentation (January 2018) on 6ix